In recent years, there has been mounting evidence pointing to the association of polyomaviruses with a wide range of human cancers. The human neurotropic polyomavirus, JCV, infecting greater than 75% of the human population produces a regulatory protein named T-antigen which is expressed at the early phase of viral lytic infection and plays a critical role in completion of the viral life cycle. Furthermore, this protein has the ability to transform neural cells in vitro and its expression has been detected in several human neuralorigin tumors. To further investigate the oncogenic potential of the JCV early protein in vivo, transgenic mice expressing JCV T-antigen under the control of its own promoter were generated. Nearly 50% of the animals developed large, solid masses within the base of the skull by 1 year of age. Evaluation of the location as well as histological and immunohistochemical data suggest that the tumors arise from the pituitary gland. As T-antigen is known to interact with several cell cycle regulators, the neoplasms were analysed for the presence of the tumor suppressor protein, p53. Immunoprecipitation/Western blot analysis demonstrated overexpression of wild-type, but not mutant p53 within tumor tissue. In addition, co-immunoprecipitation established an interaction between p53 and T-antigen and overexpression of p53 downstream target protein, p21/WAF1. This report describes the analysis of inheritable pituitary adenomas induced by expression of the human polyomavirus, JCV T-antigen in transgenic mice where T-antigen disrupts
Introduction
Pituitary adenomas are fairly common neoplasms arising from secretory cells of the anterior pituitary gland and account for 8 ± 10% of all intracranial neoplasms (Leon et al., 1994) . These tumors, which are often benign, remain undiagnosed and appear as incidental macroscopic ®ndings at autopsy in nearly 1% of the population. The majority of pituitary neoplasia are fairly well dierentiated with a slow rate of growth which remain well-circumscribed (Kovacs and Horvath, 1983) . Occasionally, tumors of the pituitary may exhibit malignant features and may invade nearby dura and bone (Kovacs and Horvath, 1983) . Pituitary tumors often express and secrete pituitary hormones leading to endocrinological diseases such as hyperprolactinemia, acromegaly, and Cushing's disease (Shimon and Melmed, 1997) . Non-functional tumors may remain undetected until slowly enlarging to a point that the optic chiasm is aected and vision is distorted usually resulting in homonymous bilateral hemioanopsia (Kovacs and Horvath, 1983) .
Previous studies on the genetics of pituitary tumors have indicated a clonal origin for sporadic tumors (Spada et al., 1994) and there is evidence of a predisposition toward tumors of the pituitary in the familial hereditary cancer syndrome, multiple endocrine neoplasia type 1 (Marx et al., 1998) . Earlier studies revealed abnormalities of the p16
INK4a gene product on chromosome 9p in a high percentage of pituitary adenomas (Woloschak et al., 1996) . Interestingly, expression of the p53 gene appears to correlate with histologic and biological aggressiveness of these tumors, and is suspected to have a role in the development and progression of pituitary origin tumors (Thapar et al., 1996) . p53 is a tumor suppressor protein which has been shown to play an important role in cell cycle checkpoint control. Furthermore, p53 function is required in some cell types for optimal programmed cell death induced by DNA damage and other agents (Levine, 1997) . Inactivation of p53 can result in deregulation of several important pathways leading to uncontrolled cell proliferation, apoptosis, etc. The transforming proteins of several DNA viruses including polyomavirus have the ability to associate with p53 and functionally inactivate this protein. The early protein of human polyomavirus JCV is composed of 695 amino acids which, similar to its well characterized counterpart from SV40, has multiple functional domains and plays an important role in control of the viral lytic cycle (Frisque and White, 1992) . JCV, which infects greater than 80% of the human population by age 15, is the established etiologic agent of the fatal demyelinating disease, Progressive Multifocal Leukoencephalopathy (PML). PML is caused by the cytolytic destruction of oligodendrocytes, the myelin-producing cells of the central nervous system (Major et al., 1992) . In addition, the oncogenic potential of JCV, has been well established in experimental animals (for reviews, see Gallia et al., 1998; Gordon et al., 1998) . There has been mounting evidence in recent years pointing to the association of JCV with a variety of human cancers, in particular those of CNS origin. Several recent studies have focused on the role of T-antigen in tumorigenesis and the cellular pathways by which JCV may be involved in transformation and tumor formation. In JCV-induced neuroectodermal-origin tumors JCV T-antigen was found in complex with p53, and the level of p21/ WAF-1, a downstream target of p53 which controls the G1 to S phase transition of the cell cycle, was decreased (Krynska et al., 1997) .
To further investigate the oncogenicity of JCV Tantigen and its association with various tumors, we developed a line of transgenic mice containing the early region of the Mad4 strain of JCV. Here we report the development of neoplastic cells within the pituitary of these mice. JCV T-antigen was detected in the tumor cells and in association with p53.
Results
To further analyse the oncogenic potential of human polyomavirus JCV early protein, T-antigen and to utilize this protein as a probe to unravel the pathways involved in cell growth control, transgenic mice containing the JCV early genome were created. Toward this end, DNA fragments containing the sequences encoding T-antigen under the control of its natural viral early regulatory sequences were microinjected into single cell embryos. Ten founder animals contained the transgene, as determined by PCR analysis of genomic DNA extracted from the tail. Of the 10 mice, one exhibited shaking of the tail suggestive of a dysmyelination phenotype described earlier (Small et al., 1986a) . This animal died at two months of age before being successfully mated.
Three founder animals appeared lethargic with disheveled fur at 2 ± 3 months of age and were sacri®ced. At necropsy, abdominal masses were discovered in each animal. Histological evaluation of the tumors revealed similarities to primitive neuroepithelial origin tumors as described previously (Franks et al., 1996) . The tumors appeared to arise from the mesentery with some local invasion of the intestine. In addition, neoplastic cells were discovered incidentally in the region of the pituitary in one animal harboring intestinal tumors. Two additional founder animals died between three and four months of age from unknown causes. None of these animals survived long enough to establish individual transgenic lines.
Founder E30 was sacri®ced at 3 months of age after exhibiting increasingly disturbing uni-directional circling. Upon necropsy, a large hemorrhagic tumor mass was discovered within the base of the skull. E30 was successfully mated before sacri®ce and heterozygous F1 animals were generated. The progeny demonstrated mendelian inheritance of the transgene and a male to female ratio of approximately 1 : 1. The animals developed normally and were indistinguishable from wild-type littermates. Approximately 50% of heterozygote E30 mice exhibited signs of illness by 1 year of age including lethargy, disheveled fur, and poor grooming. Others exhibited neurological symptoms such as circling, hemiparesis, and poor righting re¯exes. Similar to founder E30, the animals harbored massive intracranial tumors, which were solid, well-circumscribed tumors appearing in the region of the pituitary gland at the¯oor of the skull. Macroscopically, the tumors were reddishbrown solid and homogeneous masses, with small hemorrhagic areas. No evidence of necrosis or invasion into the brain parenchyma were noted. These noninvasive extra-axial tumors are observed in the pineal region, as seen in this full montage of the brain stained with hematoxylin ( Figure 1 ). The tumors often displace the cerebellum laterally and the cortex anteriorly with compression of the brainstem.
As shown in Figure 2a ,b the tumors were comprised of numerous pleomorphic cells of various sizes with abundant cytoplasm. Most cells were eosinophilic, though some were chromopholous, and they frequently arranged in an organoid pattern and formed glandular structures. Interesting, numerous giant multi-nucleated cells were observed (Figure 2c ). Some tumors showed areas of recent as well as older hemorrhage. Notably, none of the tumors demonstrated evidence of in®ltra-tion of the brain parenchyma, nor was there evidence of either metastasis or necrosis. Immunostaining with antibody to cytokeratin showed positive staining in the cytoplasm of a moderate number of cells, including multinucleated giant cells, indicating an epithelial origin for the tumor (Figure 2c ). Further, prolactin immunopositivity was detected in the cytoplasm of approximately 5% of the tumor cells suggesting that the tumor is of pituitary origin ( Figure 2d ). In addition, tumors demonstrated typical granular cytoplasmic staining with antibody to detect chromogranin as further evidence of a pituitary tumor (data not shown). The tumors were negative for CD45, synaptophysin, and afetoprotein arguing against a lymphoma, or tumors of neuroectodermal or germ cell origin. Based on histological and immunohistochemical analysis, the tumors were classi®ed as pituitary adenomas.
Interestingly, progeny from another founder, E18, developed similar tumors. Immunostaining of the second founder line, as well as several other founders with microscopic tumors, revealed the same staining patterns with ospring of E30. Founder E7, who was not successfully mated, was sacri®ced at approximately 1 year of age. A tumor in the region of the pituitary was discovered which, in contrast to those observed in founder E30 and its ospring, showed signs of local invasion into the brain parenchyma.
Next, tumor tissues from normal and ospring of E30 mice were utilized for immunoprecipitation/ Western blot analysis to assess the level of T-antigen expression. As shown in Figure 3 , a band corresponding to T-antigen protein was clearly visible in extract prepared from tumor tissue, whereas expression of the transgene was not detectable in normal tissues ( Figure  3 , compare lane 1 with lanes 2 ± 7). Of note, T-antigen was not detectable in normal brain adjacent to the tumor, supporting the observation that tumors of the E30 line exhibited no sign of local invasion.
Next, we sought to examine the level of p53 to determine if the p53 pathway may be involved in the formation of JCV T-antigen induced pituitary tumors in transgenic mice. In this study, we performed immunoprecipitation/Western blot analysis. Again, protein extract from tumor tissue and adjacent normal brain were immunoprecipitated with antibody recognizing both wild-type and mutant forms of p53, followed by Western blot analysis with the same antibody ( Figure 4a lanes 2 and 1, respectively) . As shown in Figure 4a , p53 was detected in tumor but not normal tissue.
Wild-type p53 protein is not usually detectable in normal tissues presumably due to its short half-life.
Further, p53 detected in tumor tissue is usually attributed to its mutant variants which are considered more stable. In addition, the association of wild-type p53 with several viral transforming proteins including adenovirus E1A and polyomavirus T-antigen has been shown to result in increased stability of p53 present in transformed cells (Blagosklonny, 1997) . In order to determine the p53 status of T-antigen induced pituitary tumors, selective immunoprecipitation analysis was performed with antibodies speci®c for either wild-type or mutant forms of p53, followed by Western blot analysis. As shown in Figure 4a , a band co-migrating with p53 was detectable with antibodies speci®c for wild-type p53 but not with antibodies speci®c for mutant p53 (Figure 4a , compare lanes 3 and 4 with lane 2), suggesting the expression of wild-type but not mutant p53 in these tumors. Results from sequential immunoprecipitations indicated that primary precipitations were ecient at precipitating total amounts of p53 in the extract (Figure 4 , compare lanes 2 and 3 with 5 and 6, respectively). Further, a band is detectable in lane 7, suggesting the presence of residual wild-type p53 not immunoprecipitated with antibodies to mutant p53 (compare lanes 4 and 7).
To determine the association of T-antigen and p53 in the tumor tissue extract, a similar strategy was adopted. Whole cell extract was immunoprecipitated with wild-type/mutant, wild-type speci®c, or mutant speci®c p53 antibodies. Following primary precipitation, residual supernatants were secondarily precipitated with antibody to T-antigen. The samples were then analysed by Western blot analysis in parallel for the detection of T-antigen. As shown in Figure 4b , Tantigen is present in lanes precipitated with antibodies for either wild-type/mutant or wild-type p53, indicating that T-antigen co-precipitated with p53 (lanes 1 and 2) . Interestingly, sequential immunoprecipitation with antibodies to T-antigen revealed the presence of Tantigen in the same samples (Figure 4b, lanes 4 and 5) , suggesting that T-antigen unbound to p53 is present in the tumor tissue extract as well. As anticipated, Tantigen was not detected when antibodies to the mutant form of 53 were utilized, but could be recovered during the secondary precipitation (lanes 3 and 6, respectively). Of note, bands representing Tantigen were not detectable in extract prepared from normal brain precipitated with the three p53 antibodies (Figure 4b , lanes 7 ± 9).
Next, extract from tumor and normal tissues was analysed for the presence of the p53 downstream target protein, p21/WAF1. Immunoprecipitation/Western blot analysis of extract prepared from a portion of pituitary and adjacent brain as well as spleen and kidney revealed the presence of p21/WAF1 in the tumor tissue of transgenic animals, but not other tissues (Figure 4c , compare lane 1 with lanes 2 ± 4). Precipitation of extract prepared from normal mouse tissue did not reveal the presence of p21/WAF1 ( Figure  4c , lanes 5 ± 7).
In light of this data, immunohistochemical analysis of tumor tissue for the presence of the viral oncoprotein and p53 was undertaken. As shown in Figure 5a , the majority of tumor cell demonstrate strong nuclear staining with antibodies to detect JCV T-antigen. Interestingly, immunostaining performed on the tumor tissue revealed substantial nuclear positivity Immunoprecipitation/Western blot analysis of tumor tissue for the presence of wild-type or mutant p53 using antibodies which recognize both wild-type and mutant forms (wt/mt), antibodies speci®c for wild-type protein (wt) or speci®c for the mutant form of p53 (mt). Supernatant was reserved following the primary immunoprecipitation and used for secondary precipitation as described in the text. Lane 1, extract from normal brain. (b) Immunoprecipitation/Western blot analysis to detect the presence of T-antigen. Extract from tumor tissue was subjected to immunoprecipitation with three dierent antibodies to p53 and Western blot analysis on precipitates was performed to detect JCV T-antigen. Lanes 7 ± 9, extract prepared from normal brain adjacent to tumor. (c) Immunoprecipitation/ Western blot analysis to detect the presence of p21/WAF1 in transgenic mouse tissues (lanes 1 ± 4) and tissue from normal mouse (lanes 5 ± 7) when stained for the presence of the p53 protein ( Figure 5b) . It was noted that the majority of cells in similar ®elds tumor were positive for both T-antigen and p53, suggesting that both proteins would be found to be expressed in the same cell (data not shown). Altogether, these observations indicate the expression of JCV T-antigen in pituitary adenoma cells where it is associated with wild-type p53.
Discussion
This study reports the development of pituitary adenomas in JCV T-antigen transgenic mice. Furthermore, accumulation of wild-type p53 was discovered in tumor tissue, and the p53 protein was demonstrated to be in association with the viral oncoprotein, T-antigen. Of note, p53 is rarely found mutated in human pituitary adenomas and in fact, the accumulation of p53 protein has been reported in a subset of pituitary tumors (Buckley et al., 1994; Levy et al., 1994) .
The ability of DNA tumor viruses to induce pituitary neoplasia has been demonstrated previously. HPV oncogenes E6 and E7 were able to induce neuroepithelial tumors as well as pituitary carcinomas (Arbeit et al., 1993) . In addition, it is well established that mouse polyomavirus can induce pituitary origin tumors in transgenic mice, and SV40 T-antigen under the control of tissue speci®c promoters has the potential to transform cells of the pituitary gland (Helseth et al., 1992) . Previous studies on JCV T-antigen have focused on the induction of neural-origin tumors by the JCV oncoprotein, however, this report describes the ®rst evidence of heritable pituitary neoplasia which are endocrine tumors in nature, thus expanding the range of tissues in which JCV T-antigen may be expressed. The expression of JCV T-antigen in cells of endocrine origin is an interesting phenomenon, though not without some basis in the literature. Studies on newborn Golden Syrian hamsters inoculated with JC virus described the occasional appearance of pituitary adenocarcinomas in older animals. (ZuRhein, 1983) . Factors controlling the expression of the JCV early promoter in cells of the pituitary remain to be investigated.
While initial descriptions of JCV T-antigen transgenic mice reported a dysmyelinating phenotype (Small et al., 1986a) , simultaneous experiments by the same group were the ®rst to report primitive neuroectodermal origin tumors induced by the same transgene (Small et al., 1986b) . The ability of JCV T-antigen to induce two distinct phenotypes has been attributed in part to expression of the JCV oncoprotein in the absence of viral lytic infection. Indeed, previous studies in our laboratory have demonstrated the ability of JCV T-antigen to eect myelin gene expression at the transcriptional level in dysmyelinated mice (Haas et al., 1994 ). In the current study, we did observe one founder animal who exhibited a tremor upon motion which resembled the phenotype observed in dysmyelinated JCV T-antigen transgenic mice.
It should be noted that while T-antigen protein can be detected at high levels in all tumors induced in JCV Tantigen transgenic mouse lines which we have described previously, low levels of T-antigen mRNA have been detected in normal brain and other tissues by highly sensitive RT ± PCR methods. It is likely that the low levels of T-antigen mRNA are not sucient to result in detectable levels of T-antigen by Western blotting or immunohistochemistry. Also of note, it is true that Tantigen protein has been detected in regions of the brain of mice expressing T-antigen under the control of the archetype promoter (Krynska et al., 1997) . In this case, the development of T-antigen induced medulloblastoma in the cerebellum was described. In contrast to the medulloblastoma tumors which were diuse in nature and not well delineated, the pituitary tumors described in the present study were well circumscribed and were readily separable from surrounding brain tissue. The reason for the lack of T-antigen protein at low levels in this animal model versus the previously described models is currently under investigation.
While p53 is the most frequently mutated gene in human cancers, it is rarely found mutated in human pituitary adenomas (Levy et al., 1994) . In fact, the accumulation of p53 protein has been detected in several subsets of pituitary adenomas, suggesting an increase in the half-life or stability of the protein (Buckley et al., 1994) . The increase in stability of p53 may be caused by its complexation with a viral oncoprotein such as Tantigen. Alternatively, p53's increased stability may result from a cellular process in response to T-antigen expression (Ludlow, 1993) . When in complex with Tantigen, p53 is thought to remain sequestered and unable to carry out its normal function of maintaining cells in the G1 phase of the cell cycle. Our study has shown that levels of p21/WAF-1, the downstream target of p53, are elevated within tumor tissue. This is an interesting observation in light of earlier data ascribing a positive regulatory role for wild-type p53 in the expression of p21/WAF-1 (Gartel and Tyner, 1999) . Thus, one possible explanation for an increase in p21/ WAF-1 in the tumor tissue is the presence of excess p53 unbound to T-antigen. Free p53 would then be available to induce p21/WAF-1 expression. Alternatively, one may consider that the wild-type p53 protein in complex with T-antigen retains its ability to upregulate p21/ WAF-1. However, the ability of p21/WAF-1 to be regulated in a manner independent from p53 has been well described. p21/WAF-1 upregulation in the absence of p53 can be induced by several factors such as TGF-b, TNF-a, NGF, as well as the induction of the JAK-STAT pathway (Gartel and Tyner, 1999) . Therefore, in an attempt to slow cellular proliferation and regain control of the cell cycle, regulation of p21/WAF-1 levels by an alternative p53-independent pathway may result in its elevation (Gartel and Tyner, 1999; Zeng and ElDeiry, 1996) . In any case, the high level expression of p21/WAF-1 present within these tumors does not appear sucient to slow cellular proliferation.
The transgenic model described here may closely parallel that of human pituitary tumors where wildtype p53 is accumulated within tumor cells. Further molecular and immunohistochemical analysis may lead to additional insights of mechanisms of JCV T-antigen mediated transformation and shed additional light on the role of p53 and other cell cycle regulators in tumorigenesis.
Materials and methods

Generation and analysis of transgenic animals
Transgenic mice were generated as described previously (Gordon and Ruddle, 1983) . A 3.2 kb BalI/NciI restriction fragment from the plasmid pBJC containing the JCV early promoter sequence and the coding region for the viral early gene was injected into fertilized mouse oocytes generated by mating of C57BL/6J6SJL mice. For identi®cation of mice carrying the transgene, DNA was extracted from sections of tail and subjected to PCR analysis with primers speci®c to the transgene as described previously (Franks et al., 1996) .
Antibodies utilized
SV40 T-antigen monoclonal antibody (clone pAb416, Oncogene Science) which is cross-reactive for JCV T-antigen was used for both immunohistochemical analysis and immunoprecipitation/Western blotting. For detection of p53 protein in paran-embedded mouse tumor tissue, rabbit antip53 polyclonal antibody was used (Chemicon International, Inc.) Polyclonal antibodies for immunohistochemistry to detect cytokeratin and prolactin were obtained from Dako. Antibodies against p53 for immunoprecipitation were chosen to selectively precipitate either wild-type (clone pAb246, Oncogene Science) or mutant (clone pAb240, Oncogene Science) proteins. Clone pAb421 (Oncogene Science) was used to detect both wt and mt forms of p53 by immunoprecipitation. Western blot analysis for p53 was performed with clone pAb421. Polyclonal p21/WAF1 antibody (Oncogene Science Ab-5) was utilized for both immunoprecipitation and Western blot analysis.
Histology and immunohistochemistry
Normal and tumor tissue were formalin ®xed, paran embedded, and 6 micron sections were cut for structural and immunohistochemical analysis. Paran sections were stained with hematoxylin and eosin (H & E) for routine light microscopy. Immunostaining was performed using the avidinbiotin-peroxidase complex system according to the manufacturer's instructions (Vectastain Elite ABC-Peroxidase Kit, Vector Laboratories). Brie¯y, sections were de-paranized in xylene and re-hydrated through graded ethanol to distilled water. For non-enzymatic epitope retrieval, the sections were heated to 958C for 30 min in 0.01 M Citrate (pH 6.0). The sections were allowed to cool for 20 min and then rinsed in distilled water followed by PBS. Next, the sections were incubated in methanol/3% H 2 O 2 for 20 min to quench endogenous peroxidase. In order to reduce background when detecting mouse primary antibodies in mouse tissue, an additional step utilizing either BEAT blocking solutions (Zymed) or the mouse-on-mouse kit (MOM, Vector Laboratories) was performed immediately before blocking with 5% normal serum for 2 h. After blocking, the sections were incubated with speci®c antibodies overnight at room temperature in a humidi®ed chamber. Next, secondary antibody and avidin-biotin peroxidase complex steps were performed according to the manufacturer's instructions (Vector Laboratories). Finally, the sections were developed with DAB substrate (0.02% diaminobenzidine and 0.005% hydrogen peroxide), counterstained with hematoxylin, and mounted.
Immunoprecipitation/Western blot analysis
Immunoprecipitation/Western blots were performed using extract made from normal and tumor tissue homogenized in TNN buer containing 100 mM Tris (pH 8.0), 100 mM NaCl, and 0.5% NP-40 plus protease inhibitors (aprotinin 2 mg/ml, leupeptin 10 mg/ml, pepstatin 10 mg/ml, PMSF 100 mg/ml, TPCK 100 mg/ml). One hundred and ®fty mg of total protein in 300 ml of TNN buer were incubated overnight with 5 ml of primary antibody. The samples were then incubated with 50 ml prewashed Pansorbin (Calbiochem) for 1 h at 48C. Following incubation, the Pansorbin was pelleted by centrifugation and the pellets were washed in TNN. For sequential immunoprecipitation, supernatant was reserved following the primary precipitation for use in a second round of precipitation with 5 ml of an additional antibody which was processed in a similar manner. In all cases, proteins were eluted from the washed Pansorbin pellets by resuspension in 25 ml of SDS ± PAGE sample buer containing 100 mM Tris (pH 6.8), 8% SDS, 10% glycerol, 5% b-ME, and bromphenol blue, and eluted at room temperature for 15 min.
After fractionation of the protein samples on a 1.5 mm 12% SDS ± PAGE minigel, proteins were transferred to PVDF membrane (Hybond-P, Amersham) in transfer buer containing 192 mM glycine, 25 mM Tris base, and 20% methanol, and the transblot was incubated for 1 h in TTBS solution containing 0.1% Tween-20, 100 mM Tris (pH 7.5), 0.9% NaCl, and 0.5% non-fat dry milk. After blocking, the blot was incubated with SV40 T-antigen or p21/WAF1 antibody for 2 h followed by incubation with goat antimouse IgG conjugated to alkaline phosphatase (Pierce) for 1 h. Alternatively, due to the fact that the immunoglobulin heavy chain of the primary antibody used for immunoprecipitation would obscure detection of the p53 protein as they migrate closely on SDS ± PAGE, a modi®cation to the above technique was made for Western blot analysis to detect p53. Brie¯y, protein A sepharose conjugated to alkaline phosphatase (Pierce), which recognizes only native IgG complexes, and not the denatured immunoglobulin heavy chain, was substituted as a secondary antibody. In all cases, proteins were then visualized using the CDP-STAR chemiluminescence kit (NEN-DuPont) according to the manufacturer's instructions.
